- Home
- NNBR vs MGNX Comparison
NNBR vs MGNX Comparison
Compare NNBR & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NNBR
- MGNX
- Stock Information
- Founded
- NNBR 1980
- MGNX 2000
- Country
- NNBR United States
- MGNX United States
- Employees
- NNBR N/A
- MGNX N/A
- Industry
- NNBR Industrial Machinery/Components
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- NNBR Industrials
- MGNX Health Care
- Exchange
- NNBR Nasdaq
- MGNX Nasdaq
- Market Cap
- NNBR 111.0M
- MGNX 97.2M
- IPO Year
- NNBR 1994
- MGNX 2013
- Fundamental
- Price
- NNBR $2.18
- MGNX $1.41
- Analyst Decision
- NNBR
- MGNX Hold
- Analyst Count
- NNBR 0
- MGNX 9
- Target Price
- NNBR N/A
- MGNX $5.33
- AVG Volume (30 Days)
- NNBR 205.9K
- MGNX 378.7K
- Earning Date
- NNBR 05-07-2025
- MGNX 05-13-2025
- Dividend Yield
- NNBR N/A
- MGNX N/A
- EPS Growth
- NNBR N/A
- MGNX N/A
- EPS
- NNBR N/A
- MGNX N/A
- Revenue
- NNBR $448,780,000.00
- MGNX $154,050,000.00
- Revenue This Year
- NNBR N/A
- MGNX N/A
- Revenue Next Year
- NNBR $6.01
- MGNX $45.52
- P/E Ratio
- NNBR N/A
- MGNX N/A
- Revenue Growth
- NNBR N/A
- MGNX 255.31
- 52 Week Low
- NNBR $1.58
- MGNX $0.99
- 52 Week High
- NNBR $4.67
- MGNX $5.77
- Technical
- Relative Strength Index (RSI)
- NNBR 52.23
- MGNX 39.88
- Support Level
- NNBR $1.92
- MGNX $1.30
- Resistance Level
- NNBR $2.19
- MGNX $1.58
- Average True Range (ATR)
- NNBR 0.16
- MGNX 0.11
- MACD
- NNBR 0.01
- MGNX -0.02
- Stochastic Oscillator
- NNBR 49.06
- MGNX 17.65
About NNBR NN Inc.
NN Inc is a diversified industrial company that combines engineering and production capabilities with in-depth materials science expertise to design and manufacture high-precision solutions and components. It operates in two business segments: mobile solutions and power solutions. The mobile solutions segment involves growth in the general industrial and automotive end markets. Its power solutions segment involves growth in the electrical and aerospace and defense end markets.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.